163 related articles for article (PubMed ID: 21042725)
1. Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line.
Mriouah J; Boura C; Pinel S; Chretien AS; Fifre A; Merlin JL; Faivre B
Int J Oncol; 2010 Dec; 37(6):1555-63. PubMed ID: 21042725
[TBL] [Abstract][Full Text] [Related]
2. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
[TBL] [Abstract][Full Text] [Related]
3. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
4. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
5. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
Kim SM; Kim JS; Kim JH; Yun CO; Kim EM; Kim HK; Solca F; Choi SY; Cho BC
Cancer Lett; 2010 Oct; 296(2):150-9. PubMed ID: 20444542
[TBL] [Abstract][Full Text] [Related]
9. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
11. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?
Wagenblast J; Baghi M; Mörtel S; Hirth D; Thron L; Arnoldner C; Gstöttner W; May A; Hambek M
Oncol Rep; 2009 Jul; 22(1):171-6. PubMed ID: 19513520
[TBL] [Abstract][Full Text] [Related]
12. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
13. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
15. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
Li C; Iida M; Dunn EF; Wheeler DL
Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
[TBL] [Abstract][Full Text] [Related]
19. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma.
da Costa AABA; Costa FD; Araújo DV; Camandaroba MPG; de Jesus VHF; Oliveira A; Alves ACF; Stecca C; Machado L; de Oliveira ACF; de Oliveira TB; Nicolau UR; de Lima VCC
Med Oncol; 2018 Nov; 36(1):8. PubMed ID: 30478503
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2011 Apr; 11(4):511-24. PubMed ID: 21504318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
